Medizone International, Inc. Has Filed for Patent Protection for Its AsepticSure(TM)...

Medizone International, Inc. Has Filed for Patent Protection for Its
AsepticSure(TM) Hospital Sterilization System

SAN FRANCISCO, July 13 /PRNewswire-FirstCall/ -- Following months of
engineering development and laboratory research Medizone (MZEI.PK) has filed
what it believes to be a very solid patent application for the Company's lead
product AsepticSure(TM). Medizone's CEO Edwin Marshall stated, "This U.S.
priority patent application establishes protection of our commercial rights to
this technology Internationally. We had two different firms specializing in
patent law independently research the existing art in this area so that we had
a clear understanding on how to proceed from the beginning. Fortunately, the
creative work done by our science and engineering teams has proven these new
and innovative combinations of technology when combined have greatly enhanced
bactericidal kill rates with all of the pathogens tested so far. This is not
just pumping ozone gas into a room. This patent filing not only identifies a
number of unique technologies and their protocols, it provides the scientific
data proving our ability to obtain 4.4 log/99.994% to 5 log/99.999% kill rates
for all of the pathogens of concern in hospital acquired infections. This
patent covers disinfection for rooms and their contents within all healthcare
facilities, mobile or stationary, and other critical infrastructure such as
schools and government buildings. Even as the Company prepares to move into
hospital testing later this year, we will continue to work in our new
laboratory gaining additional knowledge not only about the pathogens we have
already demonstrated outstanding success with, but against a long list of
other agents that might provide the Company with significant commercial
advantage as we advance the science and practical application of
AsepticSure(TM) beyond the hospital environment."

Medizone International, Inc., is a research and development company engaged in
developing its AsepticSure(TM) technology to decontaminate and sterilize
hospital surgical suites, emergency rooms, intensive care units, schools and
other critical infrastructure. Current trials will now be expanded to include
a hospital mock-up and then hospital beta testing of the production prototype.
Initial sales are currently targeted to commence by the end of this year.

This Press Release contains certain forward looking statements that involve
substantial risks and uncertainties, including, but not limited to, the
results of ongoing clinical studies, economic conditions, product and
technology development, production efficiencies, product demand, competitive
products, competitive environment, successful testing and government
regulatory issues. Additional risks are identified in the company's filings
made with the Securities and Exchange Commission.

Investor Relations: 800-953-3350 / web site: www.medizoneint.com
E-mail: operations@medizoneint.com

SOURCE Medizone International, Inc.

Investor Relations: +1-800-953-3350, operations@medizoneint.com